JP2007506681A5 - - Google Patents

Download PDF

Info

Publication number
JP2007506681A5
JP2007506681A5 JP2006527166A JP2006527166A JP2007506681A5 JP 2007506681 A5 JP2007506681 A5 JP 2007506681A5 JP 2006527166 A JP2006527166 A JP 2006527166A JP 2006527166 A JP2006527166 A JP 2006527166A JP 2007506681 A5 JP2007506681 A5 JP 2007506681A5
Authority
JP
Japan
Prior art keywords
antibody
use according
medicament
asthma
daclizumab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006527166A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007506681A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/031640 external-priority patent/WO2005030252A1/en
Publication of JP2007506681A publication Critical patent/JP2007506681A/ja
Publication of JP2007506681A5 publication Critical patent/JP2007506681A5/ja
Pending legal-status Critical Current

Links

JP2006527166A 2003-09-23 2004-09-21 抗il−2受容体抗体による呼吸器疾患の治療 Pending JP2007506681A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50588303P 2003-09-23 2003-09-23
US55297404P 2004-03-12 2004-03-12
PCT/US2004/031640 WO2005030252A1 (en) 2003-09-23 2004-09-21 Treatment of respiratory diseases with anti-il-2 receptor antibodies

Publications (2)

Publication Number Publication Date
JP2007506681A JP2007506681A (ja) 2007-03-22
JP2007506681A5 true JP2007506681A5 (enExample) 2007-11-08

Family

ID=34396276

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006527166A Pending JP2007506681A (ja) 2003-09-23 2004-09-21 抗il−2受容体抗体による呼吸器疾患の治療

Country Status (8)

Country Link
US (1) US20050089517A1 (enExample)
EP (1) EP1675615A1 (enExample)
JP (1) JP2007506681A (enExample)
AU (1) AU2004275860A1 (enExample)
BR (1) BRPI0414688A (enExample)
CA (1) CA2538737A1 (enExample)
RU (1) RU2006113701A (enExample)
WO (1) WO2005030252A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004289252C1 (en) 2003-11-08 2013-06-20 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from human plasma for therapeutic use
AU2009260822B2 (en) 2008-05-28 2016-09-22 Prothera Biologics, Inc. Preparation and composition of Inter-alpha inhibitor proteins from blood
AU2009325088B2 (en) * 2008-12-10 2014-06-19 Duke University Inhibition of inter-alpha trypsin inhibitor for the treatment of airway disease
US9291626B2 (en) 2011-05-12 2016-03-22 Temple University—Of the Commonwealth System of Higher Education Diagnosis and treatment of chronic obstructive pulmonary disease (COPD)
WO2014039987A2 (en) 2012-09-09 2014-03-13 Prothera Biologics, Inc. Treatment of disease using inter-alpha inhibitor proteins
EP3512539A4 (en) 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
WO2018112069A1 (en) 2016-12-13 2018-06-21 Delinia, Inc. Multivalent regulatory t cell modulators
BR112019022358A2 (pt) 2017-04-25 2020-05-19 Prothera Biologics Inc métodos para quantificar proteínas inibidoras inter-alfa
WO2020140040A1 (en) * 2018-12-29 2020-07-02 Kaleo, Inc. Devices and methods for delivery of substances within a prefilled syringe
CN114641283B (zh) * 2019-10-04 2024-07-12 R.P.谢勒技术有限责任公司 抗cd25抗体-美登素偶联物及其使用方法
US12268847B1 (en) 2021-02-10 2025-04-08 Kaleo, Inc. Devices and methods for delivery of substances within a medicament container
CN118370816A (zh) * 2024-03-22 2024-07-23 中日友好医院(中日友好临床医学研究所) Il-2/抗il-2抗体免疫复合物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411993A (en) * 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4473493A (en) * 1981-04-29 1984-09-25 Immunex Corporation Hybridoma antibody which inhibits interleukin 2 activity
US4845198A (en) * 1984-05-21 1989-07-04 Immunex Corporation Hybridoma antibody which binds IL-2 receptor
US5336489A (en) * 1985-09-05 1994-08-09 The Beth Israel Hospital Association Treatment of allograft rejection with IL-2 receptor-specific cytotoxins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU8910891A (en) * 1990-11-20 1992-06-11 National Heart & Lung Institute, The Treatment of lung diseases
WO1996032151A1 (en) * 1995-04-14 1996-10-17 Glaxo Wellcome Inc. Metered dose inhaler for fluticasone propionate
US6013256A (en) * 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
WO2000006604A2 (en) * 1998-07-27 2000-02-10 Novartis Ag Use of cd25 binding molecules in the treatment of rheumatoid arthritis or skin diseases
BR0208656A (pt) * 2001-04-06 2004-08-10 Univ Bristol Uso de moléculas ligantes de cd25 em pacientes resistentes a esteróides
EA013677B1 (ru) * 2002-11-15 2010-06-30 Генмаб А/С Человеческие моноклональные антитела против cd25 и их применение

Similar Documents

Publication Publication Date Title
KR102390714B1 (ko) 벤랄리주맙을 이용하여 천식의 악화 속도를 감소시키는 방법
JP2015527364A5 (enExample)
JP2017507139A5 (enExample)
RU2015109716A (ru) Способы лечения или предотвращения астмы посредством введения антагониста il-4r
JP2007506681A5 (enExample)
JP2007522229A5 (enExample)
JP2009511480A5 (enExample)
JP2006527193A5 (enExample)
CA2569077A1 (en) Combinations comprising antimuscarinic agents and corticosteroids
CN107073114B (zh) 使用瑞利珠单抗治疗中度到重度嗜酸细胞性哮喘
IL271132B1 (en) Dry powder aclidinium salt pharmaceutical composition for treatment of copd
RU2006113701A (ru) Лечение респираторных заболеваний антителами против рецептора il-2
JP2019528316A5 (enExample)
CA2568571A1 (en) Combinations comprising antimuscarinic agents and corticosteroids
JP2008110991A (ja) 処置方法
JP2015511625A5 (enExample)
KR102337601B1 (ko) 벤랄리주맙을 이용하여 천식 증상을 개선시키는 방법
JP2013525310A5 (enExample)
JP2014012683A5 (enExample)
TWI870471B (zh) 全身性硬化症治療用醫藥組合物
Kuhn Immunoglobulin E blockade in the treatment of asthma
Masekela et al. Asthma treatment in children: A pragmatic approach
EP4267184B1 (en) Interleukin 5 binding protein dosage regimen
US20250042985A1 (en) Interleukin 5 binding protein dosage regimen for use in treating polyangiitis, hypereosinophilic syndrome, chronic rhinosinusitis with nasal polyps (crswnp), or chronic rhinosinusitis without nasal polyps (crssnp)
JP6021952B2 (ja) 慢性閉塞性肺疾患の治療法